News
Multi-million Euro research initiative to use biomarkers to transform Crohn’s Disease
In a groundbreaking effort to change the future of Crohn’s Disease, the INTERCEPT project has launched Europe’s first-ever trial using biomarkers aimed at preventing...
Sarclisa approved in EU as first anti-CD38 therapy in combination with standard-of-care VRd to...
Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has...
Glox Therapeutics awarded share of £3m Collaborative Discovery Programme funding from Cystic Fibrosis Antimicrobial...
Glox Therapeutics, a company developing precision antibiotic therapies based on naturally occurring bacteriocins, has been awarded a share of the £3 million Collaborative Discovery...
